The US Court of Appeals for the Second Circuit has partly revived a competition case against Takeda that accuses the company of delaying generic versions of its diabetes drug Actos (pioglitazone).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
US Court of Appeals for the Second Circuit, Takeda, Teva, Actos, anti-competition, generics, Food and Drug Administration, FDA, class action,